Armistice Capital »

Elevation Oncology shares owned by Armistice Capital

Quarter-by-quarter ownership of Elevation Oncology (ELEV) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Elevation Oncology

Tip: Access up to 7 years of quarterly data

All positions including Elevation Oncology held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Elevation Oncology by Armistice Capital

Quarter filed Position value Share count Share price at filing
2023-09-30 $497k 750k 0.66
2023-06-30 $3.6M 2.4M 1.52

More positions owned by Armistice Capital

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Ptc Therapeutics I (PTCT)
Cytokinetics Com New (CYTK)
Neurocrine Biosciences (NBIX)
Incyte Corporation (INCY)
Supernus Pharmaceuticals (SUPN)
Argenx Se Sponsored Adr (ARGX)
Deciphera Pharmaceuticals (DCPH)
Agios Pharmaceuticals (AGIO)
Immunovant (IMVT)
Sanofi Sponsored Adr (SNY)
Aurinia Pharmaceuticals (AUPH)
Dentsply Sirona (XRAY)
Travere Therapeutics (TVTX)

View all positions for Armistice Capital

Top funds holding Elevation Oncology

Farallon Capital Management
Point72 Asset Management
Tang Capital Management
Balyasny Asset Management
Aisling Capital Management
venBio Partners
Braidwell
Qiming U.S. Ventures Management
Darwin Global Management
BVF
Citadel Advisors
Vanguard Group
Artal Group
Hudson Bay Capital Management
Palo Alto Investors

View all funds holding Elevation Oncology